UCB Acquires Neurona to Advance Epilepsy Cell Therapy
BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BRUSSELS, Belgium, April 17, 2026 UCB, a global biopharmaceutical leader, has announced a definitive agreement to acquire Neurona Therapeutics...
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
Basel, Switzerland – October 26, 2025: Novartis AG announced its agreement to acquire Avidity Biosciences, a U.S. biotechnology company...
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
NEW YORK, September 22, 2025 – In a landmark move shaping the future of obesity and cardiometabolic disease treatments,...
